Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of Solta Medical, Inc.
December 16 2013 - 2:00PM
Business Wire
The law firm of Finkelstein Thompson LLP is investigating
potential claims on behalf of shareholders of Solta Medical, Inc.
(Nasdaq: SLTM) (“Solta Medical” or “the Company”), concerning the
Company’s proposed acquisition by Valeant Pharmaceuticals
International, Inc. (NYSE: VRX). Under the terms of the proposal,
Solta Medical shareholders will receive $2.92 in cash for each
share of Solta Medical they own. At least one analyst has set a
target price of $4.00 for Solta Medical shares. The entire
transaction is valued at approximately $236 million.
The investigation is focused on whether Solta Medical’s Board of
Directors breached its fiduciary duty in failing to maximize
consideration to shareholders, the potential unfairness of the
consideration to shareholders, the process by which the Board
considered the transaction, and potential conflicts of interest
among the Company’s Board members.
If you are interested in discussing your rights as a Solta
Medical shareholder, or have information relating to this
investigation, please contact Finkelstein Thompson’s Washington, DC
offices at (877) 337-1050 or (202) 337-8000, or by email at
contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or
co-counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
website at www.finkelsteinthompson.com. Attorney advertising. Prior
results do not guarantee similar outcomes.
Finkelstein Thompson LLPRosalee B. C. Thomas, 877-337-1050
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jul 2023 to Jul 2024